A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

  • STATUS
    Not Recruiting
  • End date
    Nov 15, 2023
  • participants needed
    40
  • sponsor
    AbbVie
Updated on 2 June 2021
gonadotropin
leuprolide
gnrh agonist
central precocious puberty

Summary

The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either nave to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.

Details
Condition Precocious Puberty, Central Precocious Puberty, Testotoxicosis
Treatment Leuprolide Acetate (LA)
Clinical Study IdentifierNCT03695237
SponsorAbbVie
Last Modified on2 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note